Related references
Note: Only part of the references are listed.
Review
Microbiology
David M. Morens et al.
Summary: Viruses that replicate in the human respiratory mucosa cause significant mortality and morbidity and have not been effectively controlled by vaccines. This review examines challenges in developing effective mucosal respiratory vaccines and discusses possible approaches for next-generation vaccines, considering variables such as vaccine antigen configuration, dose and adjuvantation, route and timing of vaccination, vaccine boosting, adjunctive therapies, and public health vaccination policies.
CELL HOST & MICROBE
(2023)
Review
Immunology
James E. Crowe
Summary: Antibodies have been widely used for preventing and treating viral infections since the nineteenth century, and the development of potent human monoclonal antibodies has paved the way for unprecedented activities. Modifications that extend antibody half-life and the clinical development of broad and potent antibodies have the potential to make antibodies the principal tool in managing future viral epidemics. Furthermore, these antibodies are crucial for research and developing effective vaccines.
ANNUAL REVIEW OF IMMUNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Alison Tarke et al.
Summary: T cell responses induced by different vaccine platforms cross-recognize early SARS-CoV-2 variants, while memory B cells and neutralizing antibodies show significant decreases. The majority of memory T cell responses are preserved against variants, with lower recognition of Omicron by memory B cells.
Article
Immunology
Paulina Kaplonek et al.
Summary: SARS-CoV-2 mRNA vaccines provide protection against COVID-19, but concerns have arisen due to the emergence of variants that may reduce the efficacy of existing vaccines. This study investigated the binding and functional capacity of antibodies from recovered individuals and those induced by the Moderna mRNA1273 COVID-19 vaccine against SARS-CoV-2 variants of concern. While neutralizing responses to the variants decreased in both groups, the Fc-mediated responses differed. Antibodies from recovered individuals showed compromised interactions with Fc receptors, while vaccine-induced antibodies maintained their ability to interact with Fc receptors and mediate antibody effector functions. These findings suggest that mRNA vaccines may offer resilience in the humoral immune response and continue to provide protection against SARS-CoV-2 variants independent of neutralization.
Review
Immunology
Paul Moss
Summary: T cell immunity plays a central role in controlling SARS-CoV-2 infection, with early responses correlating with protection. T cell memory provides broad recognition of viral proteins, limiting the impact of viral variants and offering protection against severe disease. Current COVID-19 vaccines elicit robust T cell responses, contributing to the prevention of hospitalization or death. Therefore, the importance of T cell immunity may have been underestimated.
Review
Microbiology
Manuel Ruiz-Aravena et al.
Summary: Bats are known to carry a variety of coronaviruses and have been identified as prime reservoir hosts for emerging viruses. Since the first SARS epidemic in 2002, the understanding of bats as key hosts of coronaviruses has rapidly advanced. There are critical knowledge gaps regarding bat coronaviruses, and filling these gaps may help prevent the next pandemic.
NATURE REVIEWS MICROBIOLOGY
(2022)
Editorial Material
Medicine, General & Internal
David M. Morens et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
David W. Eyre et al.
Summary: In this study, it was found that vaccination reduces the transmission risk of the Delta variant, but the protection of the vaccine decreases over time. The effectiveness of the vaccine is higher against the Alpha variant compared to the Delta variant.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Review
Pharmacology & Pharmacy
Simone Pecetta et al.
Summary: This study reviews the immune response to SARS-CoV-2 in humans, analyzes the immunogenicity and efficacy of various vaccines currently used or in advanced clinical development, and discusses the challenges in ensuring high protective efficacy against the rapidly evolving SARS-CoV-2 virus. The manuscript was completed before the emergence of the Omicron variant and global vaccine boosting efforts.
PHARMACOLOGICAL REVIEWS
(2022)
Article
Cell Biology
M. Gordon Joyce et al.
Summary: This study developed an adjuvanted SARS-CoV-2 vaccine, which was found to induce strong immune responses and effectively eliminate the virus when challenged with high doses in nonhuman primates.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Review
Microbiology
Cesar Munoz-Fontela et al.
Summary: Animal models play a crucial role in evaluating the virulence, transmission, and immune escape of SARS-CoV-2 variants and are continuously being improved to better replicate the demographic characteristics of COVID-19.
Article
Infectious Diseases
Brittany Ober Shepherd et al.
Summary: This review examines the advances and obstacles in HIV vaccine research and their impact on the development of SARS-CoV-2 vaccines. The findings suggest that the technologies and knowledge gained from HIV research have positively influenced the development of vaccines for other viruses, including SARS-CoV-2. The investments into HIV biology have paved the way for the rapid development of safe and effective SARS-CoV-2 vaccines, presenting an opportunity for the development of HIV and other pathogen vaccines.
CURRENT HIV/AIDS REPORTS
(2022)
Article
Immunology
Su Min Pack et al.
Summary: The production of SARS-CoV-2 vaccines and the use of structural vaccinology are discussed in this article. Cryo-electron microscopy plays a crucial role in vaccine development by providing three-dimensional structures of the virus and enabling the design of new candidates to combat emerging mutants. The development of vaccines to halt the COVID-19 pandemic is a milestone for the design and manufacturing of pan-coronavirus vaccines.
Review
Immunology
Deepta Bhattacharya
Summary: Many aspects of SARS-CoV-2 have followed the principles established by viral immunology research, leading to effective COVID-19 vaccines. However, there are areas where our knowledge is lacking, such as the duration of immunity after infection or vaccination and the effectiveness of booster shots. In this article, the author discusses lessons from other infections and vaccines that can help improve durable immunity. They highlight the importance of innate sensors, antigen delivery kinetics, B cell receptors, and memory B cell subsets in antibody production and immune response. Understanding these factors better can provide a rational framework for developing vaccines that offer long-lasting immunity.
Review
Immunology
Robert C. Mettelman et al.
Summary: The lungs are constantly exposed to various substances and pathogens, thus requiring regulation of immune responses in the respiratory tract with understanding of the interactions between structural and immune cells. Studying immune responses in the lungs is crucial for treating pulmonary diseases and infections, as well as next-generation vaccine design.
Article
Infectious Diseases
Darius Mostaghimi et al.
Summary: As more people receive the SARS-CoV-2 vaccine worldwide, data is being generated to understand the vaccines' ability to reduce infection. Although randomized trials have shown that these vaccines greatly reduce symptomatic COVID-19, their effects on transmission between individuals are not well-known. This article discusses the available data on approved SARS-CoV-2 vaccines in reducing transmissibility by reducing primary infection, viral replication, transmission capacity, and symptomaticity. It also explores the potential of mucosal-targeted vaccine strategies to more effectively limit transmission compared to intramuscular vaccines. The population-level effects of approved vaccines on transmission are further examined through observational studies following clinical trials and vaccine distribution in real-world settings.
LANCET INFECTIOUS DISEASES
(2022)
Article
Economics
Ruchir Agarwal et al.
Summary: This paper finds that the elasticity of R&D effort with respect to market size is about 1/2 in the cross-section of diseases, and the R&D response to COVID-19 has been 4 to 26 times greater than that implied by its market size. Public institutions and government led incentives play a key role in driving the COVID-19 R&D effort.
JOURNAL OF HEALTH ECONOMICS
(2022)
Review
Virology
Shengle Qin et al.
Summary: The increasing cases of the novel coronavirus pneumonia have led to the need for virus research. Animal models can help evaluate the efficacy of drugs and vaccines, and provide insights into the transmission and clinical features of the virus. This review compares and analyzes the current animal models of respiratory coronavirus infection, providing important information for disease management and control.
JOURNAL OF MEDICAL VIROLOGY
(2022)
Review
Infectious Diseases
Frank Cobelens et al.
Summary: In order to eliminate tuberculosis worldwide, there is an urgent need for a new, effective, and affordable vaccine, especially for adults and adolescents in low-income and middle-income countries. A roadmap has been created to accelerate tuberculosis vaccine research and development through a participatory process. The vaccine pipeline needs to incorporate more diverse immunological approaches, antigens, and platforms. Clinical development can be expedited through validated preclinical models, agreed laboratory correlates of protection, efficient trial designs, and validated endpoints. The public health impact of new tuberculosis vaccines can be determined by understanding the demand for them in each country, integrating vaccine implementation with ongoing tuberculosis prevention efforts, considering cost, and stimulating vaccine production on a national and global scale. Investments in tuberculosis vaccine research and development should be increased, with diversification of funding sources and coordination between funders. Open science is crucial for enhancing the efficiency of tuberculosis vaccine research and development, including early and freely available publication of study findings, as well as effective mechanisms for sharing datasets and specimens. Increased engagement of industry vaccine developers, political commitment to new tuberculosis vaccines, and addressing stigma and vaccine hesitancy are also necessary. The rapid development and introduction of COVID-19 vaccines provide valuable insights for tuberculosis vaccine research and development.
LANCET INFECTIOUS DISEASES
(2022)
Article
Genetics & Heredity
Zhiyuan Chen et al.
Summary: This study analyzed global SARS-CoV-2 genomic surveillance and genomic data, finding significant variations in surveillance and sequencing capabilities among different countries. It also identified heterogeneity in sequencing percentage, sequencing technologies, turnaround time, and completeness of released metadata across regions and income groups. Moreover, it revealed a lack of proactive sharing of sequences related to variant of concerns (VOCs) in public repositories by some countries. Urgent actions are required to enhance timely and full sharing of sequences, standardize metadata files, and support countries with limited sequencing and bioinformatics capacity.
Article
Biochemistry & Molecular Biology
Ben Killingley et al.
Summary: This study establishes a new SARS-CoV-2 human challenge model and investigates the viral kinetics during primary infection. The findings have implications for public health recommendations and strategies to control the transmission of SARS-CoV-2.
Editorial Material
Medicine, General & Internal
Melanie Saville et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Review
Immunology
Joshua J. C. McGrath et al.
Summary: This article discusses recent advancements in the subphenotyping of human circulatory MBCs, revealing the phenotypic diversity and potential unique origins or subfunctions within this compartment. By using the relative induction of specific circulatory MBC subsets as a biomarker, it may provide important information for vaccine design and immunization strategies.
TRENDS IN IMMUNOLOGY
(2022)
Article
Medicine, Research & Experimental
Amalio Telenti et al.
Summary: The study of the genetics and evolution of the SARS-CoV-2 virus has played a crucial role in our understanding of the COVID-19 pandemic, providing real-time tracking of its global spread and adaptations to the human population. The virus has shown high transmissibility and has evolved new variants optimized for human-to-human transmission. Understanding the genetic makeup of the virus and its interactions with the human host is important for predicting and responding to new variants, as well as informing vaccine development.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE
(2022)
Article
Multidisciplinary Sciences
Annika Roessler et al.
Summary: Studies have shown that the omicron variant of SARS-CoV-2 is an immune escape variant. However, the BA.2 and BA.5 sub-variants of omicron have become dominant in many countries and replaced the BA.1 variant. Our analysis focused on whether BA.2 and BA.5 show further immune escape compared to BA.1. We found that unvaccinated individuals after a single exposure to BA.2 had limited cross-neutralizing antibodies to pre-omicron variants and BA.1.
NATURE COMMUNICATIONS
(2022)
Review
Immunology
David Goldblatt et al.
Summary: Antibodies against S1 epitopes provide the most accurate prediction of infection by SARS-CoV-2 coronavirus. Binding antibody titers have the highest statistical correlation. Besides neutralization, antibodies also have multiple protective functions. Cellular responses, including CD4(+) T cells and CD8(+) cells, play a significant role in antibody augmentation and viral replication control, especially in the presence of insufficient antibodies. More research is needed on mucosal responses.
IMMUNOLOGICAL REVIEWS
(2022)
Editorial Material
Immunology
Philip R. Krause et al.
Article
Medicine, General & Internal
Sarah Wulf Hanson et al.
Summary: This study estimated the proportion and duration of Long COVID symptoms in individuals with symptomatic SARS-CoV-2 infection in 2020 and 2021. The results showed differences in the prevalence and duration of Long COVID symptoms across different age and gender groups.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2022)
Review
Biochemistry & Molecular Biology
Changfa Fan et al.
Summary: This review provides a comprehensive summary of the clinical features of COVID-19 in different populations and the characteristics of various animal models for studying SARS-CoV-2. It also proposes alternative approaches for improving mouse models in the future.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2022)
Review
Infectious Diseases
Jubeda Begum et al.
Summary: The outbreak of COVID-19 has rocked the global health system and economy, and vaccination is seen as the most effective means to control the pandemic. Previous experiences with developing vaccines for SARS and MERS offer valuable insights for COVID-19 vaccine development, but rigorous testing for immunogenicity, safety, and efficacy is still needed.
TRANSBOUNDARY AND EMERGING DISEASES
(2021)
Review
Biochemistry & Molecular Biology
Alessandro Sette et al.
Summary: The adaptive immune system, consisting of B cells, CD4(+) T cells, and CD8(+) T cells, plays varying roles in different viral infections and vaccines. Studies are showing that CD4(+) T cells, CD8(+) T cells, and neutralizing antibodies all play a part in controlling SARS-CoV-2 in COVID-19 cases, emphasizing the importance of understanding adaptive immunity in combating the disease.
Article
Multidisciplinary Sciences
Aaron T. Irving et al.
Summary: Recent outbreaks of emerging viral diseases have been linked to suspected zoonotic transmission of bat-borne viruses. Bats display unique biological characteristics shaped by millions of years of adaptive evolution. Understanding the mechanisms of immune tolerance in bats could help improve human health.
Review
Biochemistry & Molecular Biology
Hyo-Dong Sung et al.
Summary: The pandemic caused by SARS-CoV-2 has led to the development of emergency use or FDA-approved vaccines, including protein-based nanoparticles, which can elicit strong immune responses. This mini-review highlights recent innovations in protein-based nanoparticle vaccines and discusses their performance in displaying antigenic domains on their surface. Recent advances in clinical trials for protein-based nanoparticle vaccines are also summarized and discussed.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Medicine, General & Internal
The Lancet
Review
Immunology
A. Kristine Moore et al.
Summary: The IVR roadmap highlights major issues and priority areas in influenza vaccine research, providing guidance for researchers to work towards new solutions and utilize innovative tools for breakthroughs in influenza vaccine R&D.
Article
Immunology
Birgitte Giersing et al.
Summary: Innovations in vaccine products are crucial for achieving equitable vaccine coverage, with the Vaccine Innovation Prioritisation Strategy (VIPS) focusing on three key innovations to address immunization barriers. To accelerate the development and uptake of these innovations, parallel actions alongside product development are necessary.
Review
Microbiology
Olivier Terrier et al.
Summary: The development of vaccines against SARS-CoV-2 was a remarkable achievement, but it also highlighted weaknesses in global pandemic response and gaps in our knowledge of coronaviruses and influenza viruses. By reviewing current knowledge of these viruses, common research challenges were identified, emphasizing the need for multidisciplinary approaches and technological innovations to improve preparedness for future pandemics.
Article
Immunology
Kathryn McGuckin Wuertz et al.
Summary: The study demonstrates that the use of SpFN-ALFQ vaccine provides protection against SARS-CoV-2-induced disease and viral replication, reducing lung pathology and viral burden.
Article
Multidisciplinary Sciences
Kevin O. Saunders et al.
Summary: This study demonstrates that immunizing macaques with nanoparticles conjugated with the receptor-binding domain of SARS-CoV-2, adjuvanted with 3M-052 and alum, can elicit cross-neutralizing antibody responses against various coronaviruses and provide protection against SARS-CoV-2. Nucleoside-modified mRNAs encoding stabilized spike proteins also induce antibody responses against different coronaviruses, suggesting potential for developing vaccines against multiple betacoronaviruses in the future.
Editorial Material
Multidisciplinary Sciences
Jon Cohen
Summary: Researchers are working on developing vaccines that can protect against multiple coronaviruses at once, aiming to enhance immunity against future coronavirus infectious diseases.
Review
Biochemistry & Molecular Biology
Matthew K. Siggins et al.
Summary: Respiratory viruses contribute significantly to the global burden of disease, and understanding the role of immunity in protection and resolution of diseases caused by these viruses, particularly in the face of challenges like COVID-19, is crucial.
TRENDS IN MICROBIOLOGY
(2021)
Article
Public, Environmental & Occupational Health
J. H. Kim et al.
Summary: Multiple global efforts are underway to develop COVID-19 vaccines, with nine organisations announcing interim analyses from phase 3 clinical testing. The US Operation Warp Speed provided significant funding for vaccine development, raising questions about how these vaccines will be used in global health settings and addressing issues related to vaccine security, justice, equity, and diplomacy.
LANCET GLOBAL HEALTH
(2021)
Article
Biochemistry & Molecular Biology
Alexandra C. Walls et al.
Summary: Understanding the protective effects of vaccines against SARS-CoV-2 variants and other sarbecoviruses is crucial for guiding public health policies. This study demonstrates that a multivalent sarbecovirus RBD-NP vaccine can protect mice from SARS-CoV-2 challenge after a single immunization, suggesting a potential dose-sparing strategy. The research also shows that antibodies induced by the multivalent sarbecovirus RBD-NPs exhibit similar resilience to various RBD residue substitutions.
Review
Microbiology
Kanta Subbarao
Summary: The development of effective SARS-CoV-2 vaccines is facing challenges in preventing asymptomatic and mild infections, potential updates required due to the emergence of variants with mutations, and concerns about the longevity of vaccine-induced immunity. Coordination in global surveillance, updating vaccines, and potential re-vaccination may be necessary to address these challenges.
CELL HOST & MICROBE
(2021)
Article
Multidisciplinary Sciences
Tyler N. Starr et al.
Summary: An ideal therapeutic anti-SARS-CoV-2 antibody should have resistance to viral escape, activity against diverse sarbecoviruses, and provide high protection through viral neutralization and effector functions. Studies have found a trade-off between in vitro neutralization potency and breadth of sarbecovirus binding in SARS-CoV-2 antibodies targeting the RBD, but identified some antibodies with exceptional sarbecovirus breadth and resistance to SARS-CoV-2 escape.
Review
Microbiology
William T. Harvey et al.
Summary: The evolution of SARS-CoV-2 has been characterized by the emergence of mutations and variants that impact virus characteristics. Manufacturers are preparing for possible updates to vaccines in response to changes in the virus population, and it is crucial to monitor genetic and antigenic changes alongside experiments to understand the impacts of mutations.
NATURE REVIEWS MICROBIOLOGY
(2021)
Article
Medicine, General & Internal
Chee-Wah Tan et al.
Summary: Survivors of SARS-CoV-1 infection who received the BNT162b2 mRNA vaccine produced potent cross-clade pan-sarbecovirus neutralizing antibodies, capable of neutralizing various variants of concern and potential human-infecting coronaviruses, indicating the feasibility of a pan-sarbecovirus vaccine strategy.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
David R. Martinez et al.
Summary: The emergence of SARS-CoV in 2003 and SARS-CoV-2 in 2019 has led to the development of universal vaccination strategies against the broader Sarbecovirus subgenus. Through the use of chimeric spike designs, high levels of broadly protective neutralizing antibodies have been induced against various high-risk Sarbecoviruses, showing potential for preventing SARS-like zoonotic coronavirus infections with pandemic potential.
Editorial Material
Immunology
Gregory A. Poland et al.
Article
Medicine, Research & Experimental
Tanushree Dangi et al.
Summary: Research shows that coronavirus vaccines and previous coronavirus infections can provide broad protection against future coronaviruses, laying the groundwork for the development of universal coronavirus vaccines.
JOURNAL OF CLINICAL INVESTIGATION
(2021)
Review
Immunology
Mark Anthony B. Casel et al.
Summary: COVID-19 is caused by SARS-CoV-2 and has a wide range of clinical manifestations. Animal models play a crucial role in research on the virus, with each model having its own strengths and limitations that can be tailored to researchers' scientific goals.
Article
Multidisciplinary Sciences
Alexander A. Cohen et al.
Summary: The study developed nanoparticles displaying the receptor binding domain (RBD) of SARS-CoV-2 and other animal coronaviruses, which induced cross-reactive antibody responses in mice. Immunization with mosaic RBD nanoparticles resulted in superior neutralization of heterologous viruses, providing a potential strategy for simultaneous protection against multiple coronaviruses.
Review
Immunology
Mark Anthony B. Casel et al.
Summary: COVID-19, caused by SARS-CoV-2, presents a wide range of clinical manifestations and the detailed mechanism underlying its severe pathogenesis is still not well understood, highlighting the importance of developing appropriate animal models for research.
Article
Immunology
Stanley A. Plotkin
Article
Immunology
Luca T. Giurgea et al.
Review
Pharmacology & Pharmacy
Yo Han Jang et al.
EXPERT OPINION ON DRUG DISCOVERY
(2020)
Review
Virology
Ashutosh Singh et al.
Review
Microbiology
Michael Letko et al.
NATURE REVIEWS MICROBIOLOGY
(2020)
Editorial Material
Medicine, General & Internal
Meagan E. Deming et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2020)
Article
Infectious Diseases
Peter J. Hotez et al.
PLOS NEGLECTED TROPICAL DISEASES
(2020)
Review
Immunology
Amrita Sekhar et al.
SEMINARS IN IMMUNOLOGY
(2020)
Review
Cell Biology
Yen-Der Li et al.
JOURNAL OF BIOMEDICAL SCIENCE
(2020)
Review
Immunology
Amy Caryn Sherman et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2019)
Article
Immunology
Birgitte K. Giersing et al.
Review
Biotechnology & Applied Microbiology
Norbert Pardi et al.
NATURE REVIEWS DRUG DISCOVERY
(2018)
Review
Biology
Andrew A. Cunningham et al.
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
(2017)
Article
Microbiology
Ben Hu et al.
Review
Immunology
Akiko Iwasaki
ANNUAL REVIEW OF IMMUNOLOGY, VOL 34
(2016)
Article
Biochemistry & Molecular Biology
Kayvon Modjarrad et al.
Article
Biochemistry & Molecular Biology
Vineet D. Menachery et al.
Review
Virology
Michael Berry et al.
Review
Oncology
Lisa E. Gralinski et al.
JOURNAL OF PATHOLOGY
(2015)
Article
Multidisciplinary Sciences
Xing-Yi Ge et al.
Article
Microbiology
Stanley Perlman
